Inflammation, Muscle Damage, Oxidative Stress, Soreness, Muscle
Conditions
Keywords
Tart Cherry, Inflammation, Muscle Soreness, Muscle Damage
Brief summary
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females.
Detailed description
The purpose of this study is to evaluate changes in force and power production, soreness, inflammation, and oxidative stress after repeated sprinting activity and powdered tart cherry ingestion in trained males and females. This study will utilize a randomized, double-blind, placebo group study design. Prior to any data collection, potential participants will be explained the protocol and then review and sign an IRB-approved consent form. Healthy male and female (n=40) participants who report regularly practicing or competing in high-intensity multi-modal resistance based exercise will complete the study protocol.
Interventions
DIETARY_SUPPLEMENTTart Cherry Extract Powder
Tart Cherry Extract Powder (ADSO Naturals). Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
DIETARY_SUPPLEMENTPlacebo
Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
Sponsors
Lindenwood University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
In a double-blind, placebo-controlled fashion, participants will be randomly assigned to one of two supplementation groups. One group will be assigned to ingest rice flour which will serve as a placebo group. The other group will be assigned to ingest 500 mg/day of Tart Cherry Extract Powder (ADSO Naturals). All study materials will be prepared into gelatin capsules of identical size, color, shape, and transparency.
Intervention model description
This study will utilize a randomized, double-blind, placebo group study design
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female (n=40) participants between the ages of 18 - 35 years of age will finish the study protocol. An even distribution of males (n=20) and females (n=20) is planned. * Participating in some form of exercise at least four days per week with at least two days consisting of some form of high-intensity exercise for the past six months. * Examples include regular gym attendance to complete resistance training, interval exercise, or participation in some form of organized physical activity involving high-speed running or other forms of high-intensity exercise. * Have a body mass index (BMI) range of 18.0 - 30.0 kg/m2. Males with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 27.5% fat will be accepted into the study. Females with a body mass index greater than 30.0 kg/m2, but a body fat percentage less than 32.5% fat will be accepted into the study.
Exclusion criteria
* Participant has a positive medical history of heart disease/cardiovascular disease, uncontrolled hypertension (140/90 or greater mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease, or Type I or Type II diabetes. * Participant has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV/AIDS), a history of cancer (except localized skin cancer without metastases or in situ cervical cancer within five years prior to screening visit. * Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea) * Positive medical history for any neurological condition or neurological disease * Currently smoke or have quit within the past six months * Current daily use of aspirin, NSAIDS, naproxen sodium, COX-2 inhibitors, or any other over-the-counter or prescribed medication indicated for pain relief. * Intake of any dietary supplement known or purported to impact muscle repair and recovery such as antioxidants, curcumin, turmeric, branched-chain amino acids, vitamin D, tart cherry, pomegranate, fish oils, or creatine monohydrate. * Individuals who indicate they are actively involved in any form of a dietary program in the past 30 days to lose weight * Participants who are lactating, pregnant or planning to become pregnant * Have a known sensitivity or allergy to any of the study products * Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data * History of alcohol or substance abuse in the 12 months prior to screening * Receipt or use of an investigational product in another research study within 28 days prior to baseline testing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sprint time | Baseline | Fastest and average sprint time during 15 30-meter sprint recorded using digitally timed timing gates |
| Changes in Creatine Kinase concentrations | 10 days | Changes in Creatine kinase concentrations following damaging exercise |
| Counter movement Jump Height | 10 days | Jump height from counter movement jump |
| Counter movement jump peak propulsive force (N) | 10 days | Peak propulsive force (N) from counter movement jump |
| Counter movement jump relative breaking force (N) | 10 days | relative breaking force (N/kg) from counter movement jump |
| Isokinetic knee extension maximal voluntary contraction. | 10 days | Peak isokinetic knee extension force (N) from a isokinetic knee extension exercise using a Biodex System 3 |
| Isometric mid-thigh pull maximal voluntary contraction | 10 days | Isometric maximal voluntary contraction peak force will be measured using an isometric mid-thigh pull assessment. Peak force production will be measured in Newtons. |
| Perceived recovery Visual Analog Scale | 10 days | Perceived recovery Visual Analog Scale ranging from 0 (worst) to 100 (best) |
| Perceived soreness Visual Analog Scale | 10 days | Perceived soreness Visual Analog Scale ranging from 0 (worst) to 100 (best) |
| Pain to Pressure threshold | 10 days | Pain to Pressure threshold from algometry (higher = less sore). Minimum values are 0 N, maximum values are 110 N |
| Changes in Creatine Kinase-myocardial band concentrations | 10 days | Changes in Creatine kinase-myocardial band concentrations following damaging exercise |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Uric Acid Concentrations | 10 days | Changes in Uric Acid concentrations |
| Peak power | 10 days | Peak power during a wingate anaerobic test |
| Changes in Protein carbonyls concentration | 10 days | Protein carbonyls concentration changes |
| Changes in 8-isoprostane concentration | 10 days | 8-isoprostane concentration changes |
| Changes in testosterone-cortisol ratio | 10 days | Testosterone-cortisol ratio changes |
| Changes in TNF-alpha concentration | 10 days | Changes in TNF-alpha concentration |
| Changes in IL-6 concentration | 10 days | Changes in IL-6 concentration |
| Changes in IL-10 concentration | 10 days | Changes in IL-10 concentration |
| Desire to exercise visual analog scale | 10 days | Desire to exercise visual analog scale (0 = not ready to train, 100 = very ready to train) |
| Pittsburgh sleepiness Scale Score | 10 days | Pittsburgh sleepiness Scale Score (lower scores indicate higher level of sleepiness) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Resting Heart Rate | 10 days | Resting heart rate at all study visits |
| Reported Adverse Events | 10 days | Self-Reported Adverse Events |
| Resting Blood pressure | 10 days | Resting Blood pressure at all study visits |
Countries
United States
Outcome results
None listed